Products
Preparation registered in Ukraine
V.I. Tseluyko, T.V. Motylevska, S.Y. Dmitriev, S.M. Karlov
Effect of irbesartan inclusion in the therapy on clinical course and prognosis in patients with persistent atrial fibrillation
The aim of study is to study the inclusion of irbetan to the standart therapy of persistent/paroxysmal atrial fibrillation on the clinical course and nearest prognosis of the patients. 20 patients were control group, study group were 35 patients. The mean dose of irbetan was 170 mg. It was determinate the positive effects of irbetan's therapy on the clinical course and nearest prognosis of this patients. The effects of irbetan are dose-dependent. It was determined ECHO-markers-predictors of unsuccessful prognosis.
Key words: atril fibrillation, irbetan, nearest prognosis, ejection fraction, left atria.